Our Network Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer Tags: #Research #Clinical Oncology #Oncology #Clinical research #AstraZeneca #Regulation Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient cohort which showed a 22% reduction in the risk of death versus chemotherapy alone.
